Cargando…
Intestinal lymphatic transport for drug delivery()
Intestinal lymphatic transport has been shown to be an absorptive pathway following oral administration of lipids and an increasing number of lipophilic drugs, which once absorbed, diffuse across the intestinal enterocyte and while in transit associate with secretable enterocyte lipoproteins. The ch...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126116/ https://www.ncbi.nlm.nih.gov/pubmed/21689702 http://dx.doi.org/10.1016/j.addr.2011.05.019 |
_version_ | 1783516080093790208 |
---|---|
author | Yáñez, Jaime A. Wang, Stephen W.J. Knemeyer, Ian W. Wirth, Mark A. Alton, Kevin B. |
author_facet | Yáñez, Jaime A. Wang, Stephen W.J. Knemeyer, Ian W. Wirth, Mark A. Alton, Kevin B. |
author_sort | Yáñez, Jaime A. |
collection | PubMed |
description | Intestinal lymphatic transport has been shown to be an absorptive pathway following oral administration of lipids and an increasing number of lipophilic drugs, which once absorbed, diffuse across the intestinal enterocyte and while in transit associate with secretable enterocyte lipoproteins. The chylomicron-associated drug is then secreted from the enterocyte into the lymphatic circulation, rather than the portal circulation, thus avoiding the metabolically-active liver, but still ultimately returning to the systemic circulation. Because of this parallel and potentially alternative absorptive pathway, first-pass metabolism can be reduced while increasing lymphatic drug exposure, which opens the potential for novel therapeutic modalities and allows the implementation of lipid-based drug delivery systems. This review discusses the physiological features of the lymphatics, enterocyte uptake and metabolism, links between drug transport and lipid digestion/re-acylation, experimental model (in vivo, in vitro, and in silico) of lymphatic transport, and the design of lipid- or prodrug-based drug delivery systems for enhancing lymphatic drug transport. |
format | Online Article Text |
id | pubmed-7126116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71261162020-04-06 Intestinal lymphatic transport for drug delivery() Yáñez, Jaime A. Wang, Stephen W.J. Knemeyer, Ian W. Wirth, Mark A. Alton, Kevin B. Adv Drug Deliv Rev Article Intestinal lymphatic transport has been shown to be an absorptive pathway following oral administration of lipids and an increasing number of lipophilic drugs, which once absorbed, diffuse across the intestinal enterocyte and while in transit associate with secretable enterocyte lipoproteins. The chylomicron-associated drug is then secreted from the enterocyte into the lymphatic circulation, rather than the portal circulation, thus avoiding the metabolically-active liver, but still ultimately returning to the systemic circulation. Because of this parallel and potentially alternative absorptive pathway, first-pass metabolism can be reduced while increasing lymphatic drug exposure, which opens the potential for novel therapeutic modalities and allows the implementation of lipid-based drug delivery systems. This review discusses the physiological features of the lymphatics, enterocyte uptake and metabolism, links between drug transport and lipid digestion/re-acylation, experimental model (in vivo, in vitro, and in silico) of lymphatic transport, and the design of lipid- or prodrug-based drug delivery systems for enhancing lymphatic drug transport. Elsevier B.V. 2011-09-10 2011-06-13 /pmc/articles/PMC7126116/ /pubmed/21689702 http://dx.doi.org/10.1016/j.addr.2011.05.019 Text en Copyright © 2011 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Yáñez, Jaime A. Wang, Stephen W.J. Knemeyer, Ian W. Wirth, Mark A. Alton, Kevin B. Intestinal lymphatic transport for drug delivery() |
title | Intestinal lymphatic transport for drug delivery() |
title_full | Intestinal lymphatic transport for drug delivery() |
title_fullStr | Intestinal lymphatic transport for drug delivery() |
title_full_unstemmed | Intestinal lymphatic transport for drug delivery() |
title_short | Intestinal lymphatic transport for drug delivery() |
title_sort | intestinal lymphatic transport for drug delivery() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126116/ https://www.ncbi.nlm.nih.gov/pubmed/21689702 http://dx.doi.org/10.1016/j.addr.2011.05.019 |
work_keys_str_mv | AT yanezjaimea intestinallymphatictransportfordrugdelivery AT wangstephenwj intestinallymphatictransportfordrugdelivery AT knemeyerianw intestinallymphatictransportfordrugdelivery AT wirthmarka intestinallymphatictransportfordrugdelivery AT altonkevinb intestinallymphatictransportfordrugdelivery |